---
title: "Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence"
description: "Formulary evidence on Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence. Covers IMPALA-2, IMPALA, IMPALA-X, SAV006-04, Long-term outcomes in five patients with Autoimmune pulmonary alveolar proteinosis treated with Molgramostim Inhalation Solution, and MOL-001. 116 evidence topics quoted from 25 sources."
canonical: "https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 IMPALA-2

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Evaluation of efficacy and safety

> “Evaluate the efficacy and safety of molgramostim for the treatment of aPAP patients”

Source: [Trapnell et al. (2024b)](https://savarapharma.com/wp-content/uploads/IMPALA-2-ERS-2024-Poster-FINAL.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Geographic participation and open-label data cutoff

| Attribute | Reported value |
| --- | --- |
| Clinical sites | “43” |
| Countries | “16” |
| Data cutoff for the reported open-label analysis | “July 3, 2025” |

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

<a id="topic-3.1.1.2-2"></a>

###### Protocol version date

> “09 October 2024”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized double-blind trial

> “The IMPALA-2 trial, a 48-week Phase 3 randomized, double-blind, placebo-controlled trial of MOLBREEVI* in 164 patients with autoimmune PAP”

Source: [Savara Inc. autoimmune PAP clinical trials page](https://savarapharma.com/our-science/what-is-apap/clinical-trials-in-apap/)

<a id="topic-3.1.1.3-2"></a>

###### Randomization and treatment-period durations

| Design component | Reported value |
| --- | --- |
| Randomization ratio, molgramostim to placebo | “1:1” |
| Double-blind treatment duration, weeks | “48” |
| Subsequent open-label treatment duration, weeks | “96” |

Source: [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Autoantibody confirmation and impaired pulmonary gas transfer

> “A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.”
> “A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj)”

Source: [Loyola Medicine](https://www.loyolamedicine.org/clinical-research/clinical-trials/NCT04544293)

<a id="topic-3.1.1.4-2"></a>

###### Stability of pulmonary gas transfer during screening

| Screening requirement | Reported threshold |
| --- | --- |
| Change in DLCO percent predicted during screening | “<15 percentage points” |

Source: [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational molgramostim dose

> “300 µg in 1.2 mL, daily”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="topic-3.1.1.5-2"></a>

###### Randomized treatment and open-label crossover

| Treatment component | Reported value |
| --- | --- |
| Double-blind active treatment | “molgramostim 300 µg” |
| Double-blind comparator | “matching placebo” |
| Administration frequency | “once daily” |
| Inhalation device | “eFlow® Nebulizer System, PARI” |

Source: [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Hemoglobin-adjusted DLCO Percent Predicted as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint definition

> “Change in % predicted DLCO from baseline to Week 24”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Clinical rationale for measuring pulmonary gas transfer

> “it is a standardized measure of pulmonary gas transfer widely used in clinical practice.”

Source: [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)

<a id="topic-3.1.1.6.1-3"></a>

###### Historical limitations of outcome-measure validation

> “2022”
> “no outcome measures have been validated for use as clinical trial endpoints in patients with aPAP”

Source: [Trapnell and Chowdhury (2022)](https://savarapharma.com/wp-content/uploads/impala-2.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Subsequent post-hoc correlations with respiratory quality of life

| Correlation between change in DLCO percent predicted and change in SGRQ Total Score | Reported result |
| --- | --- |
| Week 24 | “r=-0.46, P<0.0001; n=144” |
| Week 48 | “r=-0.46, P<0.0001; n=142” |

Source: [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Planned health economics and quality-of-life assessments

> “Health Economics and Quality of Life”
> “EuroQoL 5 Dimensions, 5 Levels (EQ-5D-5L)”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned sample size and statistical power

| Planning parameter | Reported value |
| --- | --- |
| Planned enrollment | “160” |
| Power | “90%” |
| Assumed between-group difference in DLCO percent predicted, percentage points | “5.7” |
| Assumed standard deviation, percentage points | “11” |

Source: [ClinicalTrials.gov NCT04544293 statistical analysis plan](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/SAP_001.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Randomized population

| Population | Reported number |
| --- | --- |
| Total randomized | “164” |
| Molgramostim | “81” |
| Placebo | “83” |

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Summary

The primary efficacy population includes all randomized participants, analyzed by assigned treatment. Safety analyses use participants who received at least one dose, analyzed by treatment received. The plan specifies a mixed model for repeated measures and control-based imputation for missing efficacy data. Safety analyses do not impute missing data. Multiplicity procedures differ between Japan and South Korea and the other participating regions; a nominal P-value below 0.05 therefore does not independently establish significance for every secondary endpoint.

Source: [ClinicalTrials.gov NCT04544293 statistical analysis plan](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/SAP_001.pdf); [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Analysis populations and statistical methods

| Component | Quoted specification |
| --- | --- |
| Full analysis set | “all randomized subjects” |
| Safety analysis set: minimum exposure | “at least one dose” |
| Repeated-measures analysis | “MMRM” |
| Multiplicity procedure | “Hochberg” |

Source: [ClinicalTrials.gov NCT04544293 statistical analysis plan](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/SAP_001.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Procedures for handling missing data

> “missing endpoint data will be imputed using control-based imputation”
> “There will be no missing data imputation for safety analyses.”

Source: [ClinicalTrials.gov NCT04544293 statistical analysis plan](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/SAP_001.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Double-blind treatment completion

| Treatment group | Completed the 48-week double-blind period on treatment |
| --- | --- |
| Molgramostim | “98%” |
| Placebo | “96%” |

Source: [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-3.1.1.8.1-2"></a>

###### Entry into and withdrawal from the open-label period

| Disposition measure | Reported value |
| --- | --- |
| Completed double-blind treatment and continued into open-label treatment | “160 (98%)” |
| Continued molgramostim after randomized molgramostim | “79” |
| Crossed over to molgramostim after randomized placebo | “81” |
| Discontinued treatment and withdrew during open-label follow-up through July 3, 2025 | “9” |

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic and pulmonary-function characteristics

| Characteristic | Molgramostim, 81 participants | Placebo, 83 participants |
| --- | --- | --- |
| Age, years, mean and standard deviation | “50.8 (13.0)” | “48.4 (12.7)” |
| Male, number and percentage | “44 (54.3)” | “54 (65.1)” |
| Female, number and percentage | “37 (45.7)” | “29 (34.9)” |
| DLCO percent predicted, mean and standard deviation | “52.6 (11.7)” | “52.6 (10.4)” |

Source: [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: pulmonary gas transfer at week 24

> “change from baseline”
> “DLco% at Week 24 compared with placebo (9.8% vs. 3.8%; estimated treatment difference, 6.0%; P<0.001 by comparison of least-squares means [LSMs]).”

Source: [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-3.1.1.8.3-2"></a>

###### Pulmonary gas transfer at week 48

| Measure | Molgramostim | Placebo | Estimated treatment difference | P-value |
| --- | --- | --- | --- | --- |
| Least-squares mean change from baseline in DLCO percent predicted | “11.6%” | “4.7%” | “6.9%” | “P<0.001” |

Source: [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-3.1.1.8.3-3"></a>

###### Number of participants with at least one whole lung lavage procedure over 48 weeks

| “Molgramostim (n=81)” | “Placebo (n=83)” |
| --------------------- | ---------------- |
| “6 (7.4%)”            | “11 (13.3%)”     |

Source: [Wang et al. (2025)](https://savarapharma.com/wp-content/uploads/Wang-GGO-WLL-ATS-2025-Poster-FINAL.pdf)

> “6 patients (7.4%) in the molgramostim group underwent a total of 15 WLLs and 11 patients (13.3%) in the placebo group underwent a total of 24 WLLs (Figure 5) (P=NS)”

Source: [Wang et al. (2025)](https://savarapharma.com/wp-content/uploads/Wang-GGO-WLL-ATS-2025-Poster-FINAL.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### Exploratory treadmill exercise capacity: distance walked

> “Distance Walked”
> “At Week 48”
> “The ETD was 80.6 m (95% CI, 7.9–153.2; P=0.0301)”

Source: [McCarthy et al. (2026b)](https://savarapharma.com/wp-content/uploads/McCarthy-EC-ERS-2026-Poster.pdf)

<a id="topic-3.1.1.8.3-5"></a>

###### Post-hoc biomarker analyses

> “CYFRA21-1, KL-6, and LDH”
> “Levels of biomarkers associated with aPAP disease severity decreased more in patients treated with molgramostim compared with placebo”

Source: [Inoue et al. (2026)](https://savarapharma.com/wp-content/uploads/Inoue-Biomarker-ERS-2026-Poster.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Open-label pulmonary gas transfer through week 96

> “MOL-MOL patients continued to show improvement in DLco% through Week 96”
> “overall mean increase from baseline (Weeks 0-96) of 14.7 (1.6)”

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### SGRQ Total Score: randomized treatment-period changes

| Assessment | Molgramostim change from baseline, points | Placebo change from baseline, points | Estimated difference, points |
| --- | --- | --- | --- |
| Week 24 | “-11.5” | “-4.9” | “-6.6” |
| Week 48 | “-10.7” | “-5.9” | “-4.9” |

Source: [Savara Inc. NEJM IMPALA-2 publication announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-3.1.1.8.4-2"></a>

###### SGRQ secondary endpoints and multiplicity

| “SGRQ Total Score” | “SGRQ Activity Score” |
| ------------------ | --------------------- |
| “Week 24”          | “Week 24”             |
| “P=0.0072*”        | “P=0.0149**”          |

Source: [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf)

> “P-value ≤0.05, but not statistically significant due to prespecified testing hierarchy.”

Source: [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf)

<a id="topic-3.1.1.8.4-3"></a>

###### Inferential limitation after the SGRQ Activity comparison

> “so no statistical inference was drawn with respect to subsequent secondary end points.”

Source: [Trapnell et al. (2025a)](https://doi.org/10.1056/nejmoa2410542)

<a id="topic-3.1.1.8.4-4"></a>

###### Open-label SGRQ Total Score through week 96

| Open-label population and assessment | Mean change and standard error |
| --- | --- |
| Continued molgramostim: baseline to week 96 | “-15.0 (2.6)” |
| Placebo crossover to molgramostim: week 48 to week 96 | “-6.5 (1.6)” |

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

<a id="topic-3.1.1.8.4-5"></a>

###### EQ-5D-5L descriptive system: exploratory results

> “Odds ratios of responses on the EQ-5D-5L descriptive system questionnaire numerically favored the molgramostim group on 3 of the 5 dimensions”

Source: [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf)

Additional sources: [Bonella et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2902941-1/fulltext)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Double-blind treatment-period safety

> “Symptomatic COVID-19 infection (22% molgramostim vs. 10% placebo)”
> “Worsening of aPAP (5% molgramostim vs. 14% placebo)”
> “Diarrhea (11% molgramostim vs. 2% placebo)”
> “No deaths occurred”

Source: [Trapnell et al. (2024b)](https://savarapharma.com/wp-content/uploads/IMPALA-2-ERS-2024-Poster-FINAL.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Open-label treatment-period adverse events

| Event category, number and percentage | Continued molgramostim, 79 participants | Placebo crossover to molgramostim, 81 participants |
| --- | --- | --- |
| Any adverse event | “72 (91)” | “70 (86)” |
| Serious adverse events | “17 (22)” | “23 (28)” |
| Treatment-related serious adverse events | “1 (1)” | “0” |
| Adverse events leading to death | “1 (1)” | “2 (2)” |
| Adverse events leading to drug discontinuation | “1 (1)” | “3 (4)” |

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

> “All deaths were assessed as not related to treatment.”

Source: [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The randomized comparison involved 164 participants and 48 weeks of blinded treatment. The primary endpoint measures pulmonary gas transfer rather than survival or hospitalization. Post-hoc correlations with SGRQ support clinical relevance but do not establish that DLCO is a validated surrogate for every patient-important outcome. The SGRQ Activity comparison did not meet the prespecified multiplicity requirements, and subsequent secondary or exploratory results should not be treated as independent confirmatory findings.

The week-96 extension results are uncontrolled because both groups received molgramostim after week 48. The extension reports arithmetic mean changes rather than the adjusted randomized-treatment estimates. Its three reported deaths were assessed as unrelated to treatment; the earlier statement that no deaths occurred applies to the double-blind report, not to all subsequent follow-up.

Source: [Savara Inc. autoimmune PAP clinical trials page](https://savarapharma.com/our-science/what-is-apap/clinical-trials-in-apap/); [Bonella et al. (2025b)](https://savarapharma.com/wp-content/uploads/Bonella-DLCO-ERS-2025-Poster-FINAL-1.pdf); [Ataya et al. (2025b)](https://savarapharma.com/wp-content/uploads/Ataya-QoL-PRO-ATS-2025-Poster-FINAL.pdf); [Trapnell et al. (2025a)](https://doi.org/10.1056/nejmoa2410542); [Trapnell et al. (2026)](https://savarapharma.com/wp-content/uploads/Trapnell-OLE-ATS-2026-Poster.pdf); [Trapnell et al. (2024b)](https://savarapharma.com/wp-content/uploads/IMPALA-2-ERS-2024-Poster-FINAL.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 IMPALA

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Pulmonary gas-transfer objective

> “improve the transfer of oxygen from the lungs to the blood”

Source: [Trapnell (2024a)](https://savarapharma.com/wp-content/uploads/Trapnell-IMPALA-PLS-Hospital-Practice-2024.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Geographic participation

| Attribute | Reported value |
| --- | --- |
| Clinical sites | “34” |
| Countries | “18” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.2-2"></a>

###### Trial period reported in the plain language summary

| Milestone | Reported date |
| --- | --- |
| Trial start | “February 2016” |
| Trial finish | “September 2019” |

Source: [Trapnell (2024a)](https://savarapharma.com/wp-content/uploads/Trapnell-IMPALA-PLS-Hospital-Practice-2024.pdf)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 2/3 randomized trial

> “IMPALA was a phase 2/phase 3, placebo-controlled, randomized, double-blind trial.”

Source: [Trapnell (2024a)](https://savarapharma.com/wp-content/uploads/Trapnell-IMPALA-PLS-Hospital-Practice-2024.pdf)

<a id="topic-3.1.2.3-2"></a>

###### Blinded intervention period

> “24-week, double-blind, placebo-controlled intervention period”

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.3-3"></a>

###### Allocation and extension duration

| Component | Reported value |
| --- | --- |
| Randomization ratio across continuous molgramostim, intermittent molgramostim, and placebo | “1:1:1” |
| Maximum open-label extension duration | “48 weeks” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Adult autoimmune PAP population with impaired oxygenation

| Eligibility component | Quoted criterion |
| --- | --- |
| Minimum age, years | “18” |
| Minimum alveolar-arterial oxygen difference, mm Hg | “25” |
| Resting arterial oxygen threshold, mm Hg | “75” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Continuous and intermittent inhaled regimens

| Treatment component | Quoted specification |
| --- | --- |
| Molgramostim dose | “300 μg/day” |
| Continuous regimen | “every week” |
| Intermittent regimen | “every other week” |
| Placebo during intermittent off-treatment weeks | “placebo” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Alveolar-Arterial Oxygen Difference as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Endpoint-selection rationale

> “based on investigator recommendations and extensive use in prior studies.”

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary assessment time point

| Measure | Assessment week |
| --- | --- |
| Change from baseline in alveolar-arterial oxygen difference | “24” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Randomized participants

> “138 with aPAP were randomized”

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.7.1-2"></a>

###### Treatment-group allocation

| Group | Randomized participants |
| --- | --- |
| Continuous molgramostim | “46” |
| Intermittent molgramostim | “45” |
| Placebo | “47” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Summary

The published analysis distinguishes the original full analysis set from a revised analysis that replaced invalid oxygen-gradient measurements obtained during supplemental oxygen administration. Four participants were affected: one in each molgramostim group and two in the placebo group. The revised analysis used imputation. The original full-analysis-set primary comparison was not statistically significant.

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/); [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.7.2-2"></a>

###### Invalid arterial blood-gas measurements requiring revision

| Affected group | Participants |
| --- | --- |
| Continuous molgramostim | “1” |
| Intermittent molgramostim | “1” |
| Placebo | “2” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.7.2-3"></a>

###### Analysis populations reported in the initial congress presentation

| Original analysis | Revised analysis |
| --- | --- |
| “A-aDO2* – FAS” | “A-aDO2* – Revised” |

Source: [Savara Inc. ERS presentation (2019)](https://savarapharma.com/wp-content/themes/savara/pdf/20191008_IMPALA-ERS-FINAL-REV.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Completion of the blinded intervention

| Group | Participants completing the blinded intervention |
| --- | --- |
| Continuous molgramostim | “97.8%” |
| Intermittent molgramostim | “97.8%” |
| Placebo | “93.6%” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.8.1-2"></a>

###### Open-label extension enrollment

| Disposition measure | Participants |
| --- | --- |
| Enrolled in the open-label extension | “131” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographic and pulmonary-function characteristics

| Characteristic | Continuous molgramostim | Intermittent molgramostim | Placebo |
| --- | --- | --- | --- |
| Age, years, mean and standard deviation | “54.0±13.3” | “49.2±14.1” | “46.1±14.8” |
| DLCO percent predicted, mean and standard deviation | “51.9±18.5” | “46.1±14.5” | “49.6±14.3” |
| Alveolar-arterial oxygen difference, mm Hg, mean and standard deviation | “40.5±19.6” | “40.9±20.2” | “40.2±14.3” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Initial congress report: original and revised primary analyses

| “Endpoint”          | “Units” | “Treatment effect” | “P-value” |
| ------------------- | ------- | ------------------ | --------- |
| “A-aDO2* – FAS”     | “mm Hg” | “-4.6”             | “0.1688”  |
| “A-aDO2* – Revised” | “mm Hg” | “-6.5”             | “0.0249”  |

Source: [Savara Inc. ERS presentation (2019)](https://savarapharma.com/wp-content/themes/savara/pdf/20191008_IMPALA-ERS-FINAL-REV.pdf)

<a id="topic-3.1.2.8.3-2"></a>

###### Published primary analysis: continuous molgramostim versus placebo

| Analysis | Estimated treatment difference in alveolar-arterial oxygen difference, mm Hg | P-value |
| --- | --- | --- |
| Original full analysis set | “−5.2” | “P=0.118” |
| Revised analysis with invalid measurements replaced by imputation | “−6.2” | “P=0.025” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="topic-3.1.2.8.3-3"></a>

###### Published secondary pulmonary and exercise outcomes at week 24

| Outcome | Estimated treatment difference and 95% confidence interval |
| --- | --- |
| DLCO percent predicted, percentage points | “7.8 (2.3 to 13.3)” |
| Ground-glass opacity score | “−2.5 (−3.7 to −1.2)” |
| Six-minute walk distance, m | “24.6 (−15.3 to 64.4)” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

Additional sources: [Trapnell (2024a)](https://savarapharma.com/wp-content/uploads/Trapnell-IMPALA-PLS-Hospital-Practice-2024.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### SGRQ Total Score at week 24

| Outcome | Estimated treatment difference and 95% confidence interval |
| --- | --- |
| Continuous molgramostim versus placebo, SGRQ Total Score | “−7.4 (−13.1 to −1.6)” |

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Mortality during the study

> “No deaths occurred during the study.”

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The primary result depends on the analysis used. The original full-analysis-set comparison was not statistically significant; the revised analysis replaced invalid measurements from four participants and yielded a statistically significant difference. The earlier congress presentation and the subsequently published analysis report different numerical estimates and should remain separate evidence items.

Blinded treatment lasted 24 weeks. The six-minute walk-distance confidence interval included no difference, and the subsequent extension did not retain a placebo control. These findings do not establish effects on mortality or long-term comparative safety.

Source: [Trapnell et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8083051/); [Savara Inc. ERS presentation (2019)](https://savarapharma.com/wp-content/themes/savara/pdf/20191008_IMPALA-ERS-FINAL-REV.pdf); [Trapnell (2024a)](https://savarapharma.com/wp-content/uploads/Trapnell-IMPALA-PLS-Hospital-Practice-2024.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 IMPALA-X

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Long-term safety objective

> “To investigate safety of long term use of inhaled molgramostim.”

Source: [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Participating centers and originally planned study period

| Attribute | Quoted specification |
| --- | --- |
| Participating centers | “Centres participating in the IMPALA (MOL-PAP-002) trial” |
| Estimated first enrollment | “Q1 2018” |
| Estimated last completion | “Q4 2021” |

Source: [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Uncontrolled extension study

| Design component | Quoted specification |
| --- | --- |
| Design | “open-label, non-controlled” |
| Planned treatment duration | “up to 36-month treatment period” |

Source: [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Entry after the preceding IMPALA study

> “Completed the IMPALA study”

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Intermittent inhaled molgramostim

| Treatment component | Quoted specification |
| --- | --- |
| Daily dose during treatment weeks | “300 μg/day” |
| Intermittent schedule | “1 week on and 1 week off” |

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment

| Planning measure | Participants |
| --- | --- |
| Maximum planned enrollment | “90” |

Source: [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf)

<a id="topic-3.1.3.7.1-2"></a>

###### Enrolled participants

> “n = 60”

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Descriptive safety analysis

> “Descriptive statistics were used to summarize AEs”

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Analysis populations and exposure

| Measure | Reported value |
| --- | --- |
| Full analysis set | “60” |
| Safety analysis set | “59” |
| Molgramostim exposure, patient-years | “93.4” |

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Early discontinuation of the extension

> “discontinued early as intermittent dosing did not show substantial evidence of benefit vs placebo (PBO) in the IMPALA trial”

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="topic-3.1.3.8.1-2"></a>

###### Completion of the planned treatment duration

| Disposition measure | Reported value |
| --- | --- |
| Participants completing the planned 36 months | “no patients” |

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Characteristics by preceding randomized treatment

| Characteristic | Prior continuous molgramostim, 15 participants | Prior intermittent molgramostim, 23 participants | Prior placebo, 22 participants |
| --- | --- | --- | --- |
| Age, years, mean and standard deviation | “48.7 (14.0)” | “46.7 (12.8)” | “45.6 (14.4)” |
| Male, number and percentage | “7 (46.7)” | “18 (78.3)” | “11 (50.0)” |

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Serious treatment-emergent events and mortality

| Safety finding | Quoted value |
| --- | --- |
| Participants experiencing serious treatment-emergent adverse events | “Eight” |
| Attribution of those serious events to study treatment | “none” |
| Reported deaths due to COVID-19 infection | “One” |
| Interval between final molgramostim dose and the reported death | “24 days” |

Source: [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

IMPALA-X was an uncontrolled extension that enrolled 60 participants, with 59 included in the safety analysis. It was terminated early, and no participant completed the planned 36 months. The reported exposure was 93.4 patient-years. Selection from participants who completed the preceding study and the absence of a concurrent comparator limit interpretation of adverse-event frequencies. The intermittent regimen was not pursued after the preceding IMPALA results and should not be treated as equivalent to the continuous daily regimen studied in IMPALA-2.

Source: [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf); [Bonella et al. (2022)](https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf); [Savara Inc. autoimmune PAP clinical trials page](https://savarapharma.com/our-science/what-is-apap/clinical-trials-in-apap/)

<a id="heading-3.1.4"></a>

#### 3.1.4 SAV006-04

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Pediatric efficacy evaluation

> “efficacy of inhaled molgramostim”

Source: [CTIS.eu 2024-512039-66-00](https://ctis.eu/trial/2024-512039-66-00)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Listed study location and planned dates

| Attribute | Reported value |
| --- | --- |
| Listed country | “Germany” |
| Study start | “October 22, 2025” |
| Estimated completion | “December 31, 2027” |

Source: [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label pediatric study

> “This is an interventional open-label, single arm, multi-center study in pediatric subjects, age 6 through 18 years”

Source: [ClinicalTrials.gov NCT06431776](https://clinicaltrials.gov/study/NCT06431776)

<a id="topic-3.1.4.3-2"></a>

###### Development phase and treatment-group count

| Design component | Reported value |
| --- | --- |
| Phase | “3” |
| Treatment groups | “1” |

Source: [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Specified age limits and diagnostic confirmation

> “Be ≥6 and <18 years of age”
> “positive serum anti-GM-CSF autoantibody test result”

Source: [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap)

<a id="topic-3.1.4.4-2"></a>

###### Pulmonary gas-transfer criterion

| Measure | Screening threshold |
| --- | --- |
| Hemoglobin-adjusted DLCO percent predicted | “≤70%” |

Source: [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Registered inhaled treatment

| Treatment component | Quoted specification |
| --- | --- |
| Maximum daily dose | “300 µg microgram(s)” |
| Route | “INHALATION USE” |
| Maximum treatment duration | “48 Week(s)” |

Source: [CTIS.eu 2024-512039-66-00](https://ctis.eu/trial/2024-512039-66-00)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Hemoglobin-adjusted DLCO Percent Predicted as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary endpoint

> “Change in Hb-adjusted % predicted DLCO from Baseline to Week 24.”

Source: [CTIS.eu 2024-512039-66-00](https://ctis.eu/trial/2024-512039-66-00)

<a id="topic-3.1.4.6.1-2"></a>

###### Pediatric-specific endpoint validation

No evidence found.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment

| Enrollment measure | Participants |
| --- | --- |
| Planned total | “5” |

Source: [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap)

<a id="topic-3.1.4.7.1-2"></a>

###### Analyzed population

No evidence found.

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The registered study has one open-label treatment group and a planned enrollment of five participants. No analyzed results are included in this report. Its design does not provide a concurrent placebo comparison and will provide limited precision for uncommon adverse events. The inclusion criteria specify age at least 6 years and less than 18 years, which is narrower than the older narrative description of ages 6 through 18.

Source: [ClinicalTrials.gov NCT06431776](https://clinicaltrials.gov/study/NCT06431776); [CenterWatch (2026)](https://www.centerwatch.com/clinical-trials/listings/NCT06431776/inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap); [CTIS.eu 2024-512039-66-00](https://ctis.eu/trial/2024-512039-66-00)

<a id="heading-3.1.5"></a>

#### 3.1.5 Long-term outcomes in five patients with autoimmune pulmonary alveolar proteinosis treated with molgramostim inhalation solution

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Long-term treatment outcomes

> “long-term effects of molgramostim inhalation solution”

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Case-specific treatment initiation dates

| Case | Reported initiation of molgramostim |
| --- | --- |
| Case 1 | “June 2019” |
| Case 2 | “March 2020” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Observational case series

> “real-world case series”

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Diagnostic findings in the reported cases

| Finding | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
| --- | --- | --- | --- | --- | --- |
| Anti-GM-CSF antibody | “Positive” | “Positive” | “Positive” | “Positive” | “Positive” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="topic-3.1.5.4-2"></a>

###### Prospectively defined eligibility criteria

No evidence found.

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Compassionate-use inhalation treatment

> “vibrating mesh nebuliser”
> “compassionate-use programme”

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="topic-3.1.5.5-2"></a>

###### Reported duration of molgramostim exposure

| Case | Time on molgramostim, years |
| --- | --- |
| Case 1 | “4.5” |
| Case 2 | “3.5” |
| Case 3 | “5.5” |
| Case 4 | “4 and previous 1 year in IMPALA trial” |
| Case 5 | “1.5 and previous 1 year in IMPALA trial” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using DLCO Percent Predicted as an Observational Outcome

Not applicable.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Reported case count

| Population | Reported number |
| --- | --- |
| Participants in the case series | “five” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Retrospective data collection

> “retrospective nature”

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="topic-3.1.5.7.2-2"></a>

###### Formal comparative analysis sets

Not applicable.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Ages at last reported follow-up

| Case | Age at last follow-up, years |
| --- | --- |
| Case 1 | “31” |
| Case 2 | “33” |
| Case 3 | “40” |
| Case 4 | “32” |
| Case 5 | “52” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Ages at presentation as reported in the case-series table

| Case | Age at presentation, years |
| --- | --- |
| Case 1 | “27” |
| Case 2 | “29” |
| Case 3 | “31” |
| Case 4 | “21” |
| Case 5 | “46” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Pulmonary function before treatment and at last assessment

| Measure, initial/last | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
| --- | --- | --- | --- | --- | --- |
| DLCO percent predicted | “37/91” | “36/60” | “39/87” | “62/90” | “12/44” |
| Forced vital capacity percent predicted | “64/74” | “83/122” | “52/71” | “73/88” | “54/75” |

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Case 5: return to employment

> “he has returned to work.”

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="topic-3.1.5.8.4-2"></a>

###### Standardized patient-reported outcome scores

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Reported serious adverse events

> “There were no reported serious adverse events in these five patients while receiving molgramostim and the treatment has been well tolerated.”

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

This retrospective series describes five participants without a concurrent comparator. Treatment exposure and follow-up duration varied, and two cases included preceding IMPALA exposure. The reported pulmonary-function improvements cannot establish a comparative treatment effect. Absence of reported serious adverse events in five cases does not estimate the frequency of uncommon harms, and the qualitative return-to-work report is not a standardized quality-of-life assessment.

Source: [Montaño et al. (2025)](https://savarapharma.com/wp-content/uploads/Long-Term-Outcomes-in-Five-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-Treated-with-Molgramostim-Inhalation-Solution_ERJ-2025.pdf)

<a id="heading-3.1.6"></a>

#### 3.1.6 MOL-001

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Safety and clinical pharmacology

> “safety, PK and PD”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study location and enrollment period

| Attribute | Quoted specification |
| --- | --- |
| Clinical research facility | “Celerion” |
| Location | “Belfast” |
| Enrollment period | “May through September 2015” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Phase 1 randomized pharmacology study

> “randomised, placebo-controlled, blinded, phase 1 clinical trial”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Healthy nonsmoking adult population

> “life-long non-smokers”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.4-2"></a>

###### Age limits

| Eligibility measure | Reported range |
| --- | --- |
| Age, years | “18 to 55” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Single ascending-dose cohorts

| Cohort | Molgramostim dose, µg | Participants |
| --- | --- | --- |
| First active-dose cohort | “150” | “4” |
| Second active-dose cohort | “300” | “4” |
| Third active-dose cohort | “600” | “4” |
| Pooled placebo cohort | “placebo” | “6” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.5-2"></a>

###### Multiple ascending-dose cohorts

| Cohort | Daily molgramostim dose, µg | Participants |
| --- | --- | --- |
| First active-dose cohort | “300” | “9” |
| Second active-dose cohort | “600” | “9” |
| Pooled placebo cohort | “placebo” | “6” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.5-3"></a>

###### Repeated-dose duration

| Treatment component | Reported duration |
| --- | --- |
| Consecutive daily doses in the multiple ascending-dose study | “six” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Total enrollment

> “42 subjects were enrolled”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.7.1-2"></a>

###### Enrollment by study component

| Study component | Participants |
| --- | --- |
| Single ascending dose | “18” |
| Multiple ascending dose | “24” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Pharmacokinetic analysis method

> “Non-compartmental PK”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.7.2-2"></a>

###### Multiplicity

> “All reported p-values were two-sided without adjustment for multiple testing.”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.7.2-3"></a>

###### Formal analysis-set definitions

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Study completion

| Disposition measure | Participants |
| --- | --- |
| Enrolled and completed the study | “42” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Overall demographic characteristics

| Characteristic | Reported value |
| --- | --- |
| Age, years, mean and standard deviation | “33.7±11.7” |
| Age range, years | “(18, 53)” |
| Male, number and percentage | “40 (95)” |
| Female, number and percentage | “2 (5)” |
| White, number and percentage | “40 (95)” |
| Black, number and percentage | “2 (5)” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Pharmacokinetic results in healthy volunteers

> “healthy people”
> “peaked at 2 hours for all three doses and had an elimination half-life of 1.7±0.0 to 5.9±0.9 hours”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.8.3-2"></a>

###### Disease-specific efficacy

Not applicable.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Adverse events by dosing component

| Study component | Molgramostim: participants with adverse events | Placebo: participants with adverse events |
| --- | --- | --- |
| Single ascending dose | “7 (58%)” | “4 (67%)” |
| Multiple ascending dose | “15 (83%)” | “6 (100%)” |

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-3.1.6.8.5-2"></a>

###### Serious adverse events

> “No serious AEs occurred”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

This study enrolled 42 healthy participants, including two women, and evaluated single doses or six consecutive daily doses. It does not establish efficacy in autoimmune pulmonary alveolar proteinosis or the safety of prolonged daily treatment. The sample size and short exposure limit assessment of uncommon or delayed adverse events. Statistical comparisons were not adjusted for multiple testing.

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

## Related pages
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations.md)
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Economic information and modeling report](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: References](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: prevalence by geography](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses.md)
